CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2013. The put-call ratio across all filers is 0.83 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $378,000 | -72.9% | 15,000 | -70.0% | 0.01% | -72.0% |
| Q1 2015 | $1,394,000 | +155.8% | 50,000 | +66.7% | 0.02% | +150.0% |
| Q4 2014 | $545,000 | +12.6% | 30,000 | +50.0% | 0.01% | +11.1% |
| Q4 2013 | $484,000 | -45.4% | 20,000 | -20.0% | 0.01% | -47.1% |
| Q3 2013 | $886,000 | +89.3% | 25,000 | -16.7% | 0.02% | +88.9% |
| Q2 2013 | $468,000 | – | 30,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,006 | $3,457,000 | 100.00% |
| Meditor Group Ltd | 6,312,700 | $3,179,000 | 0.62% |
| TSP Capital Management Group, LLC | 1,328,207 | $669,000 | 0.34% |
| GREAT POINT PARTNERS LLC | 804,483 | $405,000 | 0.06% |
| Telemetry Investments, L.L.C. | 252,300 | $127,000 | 0.05% |
| Centiva Capital, LP | 187,749 | $95,000 | 0.02% |
| Benchmark Capital Advisors | 54,400 | $27,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 639,800 | $322,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 79,400 | $40,000 | 0.01% |
| LMR Partners LLP | 408,846 | $206,000 | 0.01% |